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Advances in genome analysis, accompanied by the assembly of large patient cohorts, are making possible
successful genetic analyses of polygenic brain disorders. If the resulting molecular clues, previously hidden
in the genomes of affected individuals, are to yield useful information about pathogenesis and inform the dis-
covery of new treatments, neurobiology will have to rise to many difficult challenges. Here we review the un-
derlying logic of the genetic investigations, describe inmore detail progress in schizophrenia and autism, and
outline the challenges for neurobiology that lie ahead.We argue that technologies at the disposal of neurosci-
ence are adequately advanced to begin to study the biology of common and devastating polygenic disorders.Introduction
Genomes encode the keymacromolecular building blocks of our
cells, RNA, and proteins. In concert with intracellular and extra-
cellular signals, our genomes regulate the times, places, quanti-
ties, and cell-type-specific patterns of expression of messenger
RNAs (mRNAs) that give rise to proteins and of RNAs with inde-
pendent functions. These macromolecules, in turn, direct the
synthesis and trafficking of essentially all other molecules within
cells. Analysis of the completed genome sequences of many or-
ganisms, together with biochemistry, physiology, and other dis-
ciplines, have made it possible to identify many if not essentially
all of the genes that encode components of receptors, ion chan-
nels, synaptic proteins, and other molecular complexes of cen-
tral interest to neurobiology. Increasingly powerful technologies,
grounded in genetics and molecular biology, permit neuroscien-
tists to manipulate the genomes of cells and model organisms to
understand both normal function of the nervous system and dis-
ease processes (Cong et al., 2013; Fenno et al., 2011; Wang
et al., 2013). Currently, information derived from genes and
genomes provides neuroscientists with molecular clues to the
properties of the many thousands of neuronal and glial cell types
in the brain, to functional properties of brain circuits, and ulti-
mately to important aspects of cognition, emotion, and behavior.
Recognition of the importance of genetic and genomic infor-
mation is not meant as an embrace of simplistic genetic deter-
minism, which was discarded by neuroscientists long ago based
on the evidence—one obvious refutation is the frequent discor-
dance of monozygotic twins (who share 100% of their DNA
sequences) for important phenotypes, including both normal
variation and disease phenotypes including schizophrenia and
mood disorders. Such discordance, for the most part not yet un-
derstood in detail, is grounded in complex interactions of genes
with stochastic and environmental factors that influence brain
development, maturation, and function. That said, genomes
carry enormous biological influence: the remarkable similarities578 Neuron 80, October 30, 2013 ª2013 Elsevier Inc.of basic brain structure and functionwithin species are testimony
to the central significance of the genetic blueprint. A recent
demonstration that human pluripotent stem cells in vitro
(extremely distant from a natural developmental environment)
can give rise to cerebral organoids with discrete recognizable
brain structures and significant features of a cerebral cortex
(Lancaster et al., 2013) serves as a remarkable reminder of the
information contained in genomes—even if the resulting organo-
ids are only pale simulacra of a human brain.
Genetic information is particularly important to neurobiologists
studying brain disease because the human brain is, both for
ethical and practical reasons, generally inviolable. Scientists
studying the biology of cancer or immunologic diseases, for
example, can have direct access to diseased tissues obtained
from surgical specimens or blood. The resulting cells can be
examined for somatic mutations, epigenetic marks, patterns of
gene expression, and other molecular indicia. In contrast, for
the most part, the human brain can only be examined indirectly
in life. Thus, when disorders of the CNS have a significant hered-
itary component of risk, the ability to obtain molecular clues from
genetic analysis may create the most effective current opportu-
nities for scientific investigation. The utility of genetic insights is
particularly salient in brain disorders that affect evolutionarily
recent brain circuits and regions or that for other reasons have
been difficult to model in animals. These include common psy-
chiatric disorders such as autism, schizophrenia, bipolar disor-
der, and major depression as well as late-onset versions of
neurodegenerative disorders such as Parkinson’s disease and
Alzheimer’s disease. In the case of the psychiatric disorders,
the relative lack of neuropathology that can be analyzed in post-
mortem tissue makes genetic information even more valuable as
a source of molecular clues to pathogenesis.
Psychiatric disorders have long been recognized to cluster in
families even though they do not segregate in simple, Mendelian
fashion. Twin and adoption studies demonstrated that familiality
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the molecular basis of these serious and disabling disorders is
hidden in DNA sequence variation. Two factors have made it
possible during the last 5 years to reveal such heretofore hidden
information: technological innovation in genome analysis and
recognition of the need for scale. Advances in genomics made
it possible to prosecute large-scale unbiased genome-wide
searches both cheaply—the cost of sequencing DNA has
declined approximately one million-fold in the last decade—
and accurately. At the same time, a new appreciation of the scale
of analysis required to successfully attack heterogeneous, poly-
genic disorders has led to the examination of tens of thousands
of genomes, and thus, finally, to genetic findings that replicate
across large studies. For example, large-scale genetic analyses
(involving 80,094 individuals, both patients and controls) have
now contributed to recognition of 110 loci that influence suscep-
tibility to multiple sclerosis (International Multiple Sclerosis
Genetics Consortium, 2013). Among the psychiatric disorders,
genetic analyses have arguably yielded the first substantial, if still
early, insights into molecular mechanisms of disease. Such find-
ings across many common brain disorders promise to make the
coming 25 years very different from the previous 25, not only with
respect to understandings of pathogenesis but also—it is to be
hoped—effective therapeutics. Such success will only come to
pass, however, if neurobiology rises to the difficult challenge of
putting genetics results to work.
How Our Genomes Operate—and How They Do Not
A naive but pervasive view of human genetic variation sees the
human genome as an optimized end product of evolution. In
this view, a human genome, like a Shakespearean sonnet, is
perfectly composed, with a place for everything, and everything
in its place. Such a genome, perfected through many rounds of
natural selection, brings us a long and disease-free life, unless
a new mutation or an unfortunate calamity of environment
causes an illness. In fact, analysis of the sequences of thousands
of human genomes demonstrates that far from conforming to
some uniform model of optimization, our genomes teem with
functional variation. The two haploid genomes that we inherit
from our parents differ at millions of sites (Abecasis et al.,
2010). Several thousand variants affect the copy number of
large, multikilobase genomic segments (Handsaker et al.,
2011; Conrad et al., 2010). Each genome has thousands of var-
iants that affect the expression of nearby genes, with different
sets of regulatory variants acting in different tissues (Nica
et al., 2011; Fu et al., 2012). Each diploid human genome has
about 100 gene-disrupting variants, from large deletions to sin-
gle-nucleotide nonsense variants that ablate the functions of
specific genes; in any individual, some 20 of these genes may
be inactivated in both copies (MacArthur et al., 2012). Thousands
of protein-coding genes harbor missense variants that may influ-
ence their function in complex ways (Abecasis et al., 2010).
The human genome as it exists in real human populations,
then, is less a Shakespearean sonnet than a collection of seven
billion drafts. In any genome, we can readily find thousands of
variants that look functional on paper, many of which may be
confirmed as functional by some laboratory assay. However,
most apparently functional variants have, at least to date, nodemonstrated association to disease phenotypes when evalu-
ated in large numbers of individuals. In sum, it is easy to find
variation, even functional variation, but against this complex
background it is very difficult to identify gene variants that
contribute to any particular illness phenotype. This challenge
notwithstanding, it is clear that the genome is the right place to
look formolecular underpinnings of illness. Studies of psychiatric
disorders that compared the concordance rates of monozygotic
versus dizygotic twin pairs estimate heritability at 0.81 for schizo-
phrenia (Sullivan et al., 2003), 0.75 for bipolar disorder (Smoller
and Finn, 2003), and 0.80 for autism spectrum disorders (Ronald
and Hoekstra, 2011). Some assumptions inherent in twin studies
have been questioned, but recent analytical techniques, which
use genome-wide molecular data to derive unbiased estimates
of heritability, strongly confirm a significant role for inheritance
in shaping risk (Lee et al., 2012; Yang et al., 2010). One can
conclude that insights about the molecular nature of brain
illnesses are encoded in the sequences of individual human
genomes. The challenge is to find the variants that matter,
among the far-larger number of variants that do not. The chal-
lenge is heightened given that variants do not act in isolation or
on isogenic backgrounds, nor can human developmental envi-
ronments be held constant as genomes vary.
Mendelian Brain Disorders
Over the past two decades, it has become increasingly straight-
forward to identify the causal genes for highly penetrant, Men-
delian (monogenic) human diseases. Among monogenic brain
disorders, significant early discoveries included the identification
of CGG repeats within the FMR1 gene as the cause of Fragile X
syndrome (Fu et al., 1991), identification of the genetic cause of
Huntington’s disease (The Huntington’s Disease Collaborative
Research Group, 1993), and the demonstration that mutations
in the MECP2 gene produced Rett syndrome (Amir et al.,
1999). Identification of these causative genes made it possible
to develop awide range of tools ranging from antibodies to trans-
genic mice, although successful clinical trials of therapies based
on these discoveries have been slow to follow.
One reason for the difficulty in discovering therapeutics is that
apparently monogenic disorders are not always as simple to
analyze as might initially appear. Affected individuals for any
given disorder may have different mutations in the causative
gene, which may influence such features as age of onset, dis-
ease severity, and treatment response. For example, in Rett syn-
drome, diverse mutations have been identified in the MECP2
gene (Lee et al., 2001). Moreover, some MECP2 mutations pro-
duce not Rett syndrome but other neuropsychiatric symptoms
such as obsessive-compulsive disorder and attention-deficit
hyperactivity disorder; some individuals with well-diagnosed
Rett syndrome do not have MECP2 mutations at all (Suter
et al., 2013). In addition, mutations in a single causative gene
may only be a portal to far greater molecular complexity. Thus,
for example, FMR1, which is a neuronal polyribosome-associ-
ated RNA binding protein, has been shown to affect the transla-
tion of 842 mRNA transcripts (Darnell et al., 2011) each with their
own ‘‘downstream’’ biology; many of these individual targets are
now being implicated for subtler contributions to complex, poly-
genic disease.Neuron 80, October 30, 2013 ª2013 Elsevier Inc. 579
Figure 1. Different Kinds of Genetic
Variation and Different Approaches to
Genetic Analysis Are Influenced by Human
Population History
(A) Humans have an eccentric population history,
in which small, ancestral populations rapidly
expanded into a population of some seven billion
individuals.
(B) Genetic variants that have arisen recently
in human history, including new mutations, are
generally ascertained by genome sequencing.
(C) Polymorphisms that were already present
in the small, ancestral populations can be
systematically evaluated for relationship to
phenotypes, on thousands of genetic back-




The unexpected complexity of many monogenic brain disorders
pales in comparison with the emerging complexity of common
polygenic brain disorders, a challenge that is only now coming
into view. Because severe, highly penetrant mutations often pro-
ducemarked decrements in reproductive fitness, they tend to be
rare. In contrast, many common human illnesses result from the
interaction of a large number of genes (polygenicity) in combina-
tion with nongenetic risk factors. Moreover, disease phenotypes
tend to result from different combinations of genetic (and likely
nongenetic) risk factors in different families and individuals.
The use of the term ‘‘risk factor’’ rather than ‘‘cause’’ indicates
that among polygenic disorders, any individual sequence variant
(or environmental factor) acts in a statistical rather than deter-
ministic fashion. No single genetic variant is necessary or suffi-
cient for the disorder phenotype and thus cannot be used to
predict phenotype except in a probabilistic manner.
Several important genetic results support polygenic models,
for example, in schizophrenia and autism. The first is the finding
that large numbers of common variants shape an individual’s dis-
ease risk. Statistical geneticists define a ‘‘polygene’’ from large
constellations of common alleles that are observed (in one
cohort) at slightly higher frequencies in schizophrenic patients
than controls. When such alleles are subsequently evaluated in
other cohorts, schizophrenic patients are found to carry more
such alleles (on average) than control subjects do. (Purcell
et al., 2009).Within families, schizophrenic children of unaffected
parents also tend to have inheritedmore than the 50%of such al-
leles that they would be expected to have inherited by chance
from parents heterozygous at the relevant loci (Ruderfer et al.,
2011). These results suggest that one important component of
genetic risk for a polygenic disorder such as schizophrenia arises
frommanysmall genetic nudges, rather thanasingle, hard shove.
The polygenic model is also supported by rare alleles of larger
effect. For example, a substantial minority of autistic patients
(about 5%–10%), but only a small fraction of the general popula-
tion (about 1%), have de novo deletions and duplications of large
(>500 kb) genomic segments in their genomes. This excess in
patients indicates that such ‘‘copy number variations’’ (CNVs)
contribute to the patients’ phenotypes. However, these CNVs580 Neuron 80, October 30, 2013 ª2013 Elsevier Inc.are widely distributed across the genome, at more than 100
different loci. Only a few loci show recurrent mutations, and
these recurrent mutations account for only about 1%–2% of
patients. The statistical distribution of influences across the
genome suggests that hundreds of different human genes can
mutate to influence autism risk (Sanders et al., 2011).
Perhaps the emerging polygenicity of mental disorders,
involving many hundreds, and perhaps more than a thousand,
genetic loci, should not have come as a surprise. Cognition,
executive function, and emotional regulation are not the result
of simple, five-protein metabolic pathways. The assembly of
synapses and neuronal circuits involves complex biological pro-
cesses that recruit thousands of gene products. The implications
of polygenicity were not initially recognized, which doomed older
linkage studies of psychiatric disorders in the 1980s and 1990s
to failure. Small studies in the 1990s and early 2000s that at-
tempted to show association of plausible biological candidate
genes with disease suffered a similar fate. They produced
equivocal results that ultimately failed the test of replication.
Only when recent unbiased, genome-wide studies were
adequately sized, did they succeed in distinguishing disease-
associated variants from genome-wide statistical fluctuations.
Genome Variation, Rare and Common
To understand how human gene discovery approaches work,
one needs to take a brief detour through human population his-
tory. Humans have an eccentric population history: although
some seven billion humans currently inhabit the earth, we were
a far-smaller species only 100,000 years (about four thousand
generations) ago, and even a significantly smaller population
150 years (seven to eight generations) ago. The dramatic expan-
sion of human populations from smaller groups of ancestors has
profoundly shaped the patterns of variation that exist in human
genomes. It also defines some of the key opportunities for
discovering the sequence variants that contribute to phenotypes
(Figure 1).
Studies of Rare Variation
An intriguing set of genetic variants has arisen in rapidly expand-
ingmodern populations, even involving newmutation in themost
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both rare and relatively unfiltered by natural selection; thus,
they could in principle include more deleterious mutations. An
early view of the contributions of rare variants came from the
observations of large CNVs in the genomes of several percent
of autism and schizophrenia patients. Such CNVs appear
to confer substantial increases in risk. Interestingly, they have
proven to be only partially penetrant, increasing risk from a back-
ground rate of about 0.5%–1.0% to about 4%–20%. Because
most of the recurrent CNVs are large (hundreds of kilobases)
and affect the dosage of many genes, it has been difficult to
derive actionable neurobiological insight from them.
Many more rare variants exist at the fine-scale of single-nucle-
otide variants and small indels (insertions or deletions). An impor-
tant advance in the ability to identify and study rare variants
comes from innovations in sequencing technology. Today the
protein-coding parts of a patient’s genome (the ‘‘exome’’)
can be sequenced for well under $1,000, enabling exome-
sequencing studies of hundreds of patients. As in the case of
common variants, it is challenging is to distinguish the rare
variants that contribute to a phenotype, from the background
of other rare variation that is present in each genome.
To reduce the background created by the hundreds of protein-
altering variants in each genome, one common study design
sequences father-mother-proband trios, then focuses on those
protein-altering mutations in the proband that are de novo
mutations, i.e., that were not inherited from either patent. The
challenge in this analysis comes from the fact that protein-
altering mutations unrelated to disease arise in the general pop-
ulation at an appreciable rate. Disease-predisposing variants are
not immediately distinguishable from this background, except to
the extent they recur in the same genes in different individuals
with the disease under investigation.
To date, the most convincing implication of individual genes
has come from studies of congenital and child-onset disorders
such as autism, intellectual disability, and pervasive develop-
mental delay. For autism, four large studies of father-mother-
offspring trios collectively ascertained de novo mutations in
more than one thousand autism patients (Sanders et al., 2012;
O’Roak et al., 2012a; Neale et al., 2012; Iossifov et al., 2012).
Analysis of the trios from these studies, when considered jointly,
identified CHD8 and SCN2A as genes harboring recurrent,
disruptive mutations in autistic patients. Deeper sequencing of
44 genes in another 2,446 patients also observed recurrent
mutations in DYRK1A, GRIN2B, TBR1, PTEN, and TBL1XR1
(O’Roak et al., 2012b). Notably, studies of de novo mutations
in children with severe intellectual disability identify mutations
in some of these same genes (Rauch et al., 2012; de Ligt et al.,
2012). De novo mutations may make a smaller contribution to
teen or adult-onset disorders such as schizophrenia: studies
have not yet found statistically convincing levels of recurrent
mutations in individual genes, though one study reports a
greater-than-chance rate of mutations in cortically expressed
genes as a group (Girard et al., 2011; Xu et al., 2012; Gulsuner
et al., 2013).
The results of exome sequencing studies support models
of significant polygenicity for autism and schizophrenia. Iossifov
and colleagues estimate from the statistical distribution of disrup-tive mutations across genes that 350–400 autism susceptibility
loci exist in the genome—an estimate broadly consistent with
estimates from the distribution of de novo CNVs (Iossifov et al.,
2012; Sanders et al., 2011). Lim et al. (2013) estimate that about
5% of autism cases may also arise from noncomplementing
genetic variants at dozensof different loci.Given thispolygenicity,
larger studies will be required to identify concentrations of muta-
tions in additional genes at a level that is statistically meaningful.
Insights from Common Variation
Another powerful way to connect genome variation with com-
plex phenotypes arises from the genetic variation that was
present in the small, ancient populations that subsequently
expanded across the world (Figure 1). Such alleles are today
found among millions of people on almost every continent, in
fact present in almost any large assembly of people. These com-
mon variants are finite and modest in number, numbering in the
millions (rather than the billions), and can be cataloged by
sequencing a few hundred individuals (Abecasis et al., 2012).
Targeted molecular assays for these variants are then arrayed
onto inexpensive array-based platforms for genome-wide SNP
genotyping. This makes it possible to evaluate the reservoir of
common polymorphism, more or less systematically, by using
such arrays together with statistical techniques that impute the
states of untyped variants from the typed ones (Li et al., 2009).
The low cost of such platforms (many cost less than $100 per
genome) allows this approach to be brought to bear on many
thousands of genomes. This sample size is critical for rigorously
measuring the effect of a variant by studying it on thousands of
genetic backgrounds and in diverse environments.
Common-variant association studies for psychiatric disorders
appeared for many years to be unsuccessful, particularly when
compared to the extensive gene discovery from common-
variant approaches in autoimmune disease, cardiovascular
disease, metabolic disease, stature, body mass, and other
phenotypes. With hindsight, the problem was that studies of
schizophrenia, the most deeply studied psychiatric disorder to
date, were simply underpowered. These studies were initially
being pursued at a scale insufficient to find all but the strongest
effect (theHLA locus) in a disorder as highly polygenic as schizo-
phrenia. As international collaborations and focused research
resources have expanded sample size, common-variant associ-
ation studies are finding far more genetic influences on risk. In
schizophrenia, as sample sizes in international meta-analysis
by the Psychiatric Genomics Consortium (PGC) reached
10,000 cases in 2011, another five schizophrenia loci were un-
covered (Lee et al., 2012). A more recent expansion of sample
size to include a large Swedish cohort found 22 loci with
genome-wide levels of significance (Ripke et al., 2013). Most
excitingly, an ongoing ‘‘stage 2’’ analysis by the PGC,
comprising some 35,000 cases and a larger number of controls,
is on a path to find 100 ormore such influences with high levels of
confidence. The genomic segments implicated in common-
variant association studies are typically tens of kilobases long.
Amajority of them span just one to three genes, and about a third
point crisply to a single gene. Such studies are nominating a sub-
stantial number of individual genes for biological analysis.
Indeed, common-variant studies are creating an initial molecularNeuron 80, October 30, 2013 ª2013 Elsevier Inc. 581
Figure 2. Emerging Genetic Evidence on Complex Brain Disorders
Converges on Specific Molecular Complexes
(A) Multiple subunits of voltage-gated calcium channels are among the
genome’s strongest associations to schizophrenia and bipolar disorder.
(B) Genes encoding the postsynaptic components of excitatory synapses are
implicated by both rare and common variants in schizophrenia.
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and autism when sample sizes catch up to the levels reached in
schizophrenia. (Today, they are several times lower—approxi-
mately 7,500 and 3,000 cases, respectively, in published studies
for bipolar disorder and autism [Psychiatric GWAS Consortium
Bipolar Disorder Working Group, 2011; Anney et al., 2010; Weiss
et al., 2009].)
Genetic Evidence Converges on Specific Molecular
Complexes
Perhaps the most exciting aspect of the emerging schizophrenia
genetics results is that constellations of genetic findings are
converging on identifiable molecular complexes and pathways.
Voltage-Gated Calcium Channels
Common variants in the genes encoding multiple subunits of
voltage-gated calcium channels are strongly implicated in
schizophrenia and bipolar disorder (Figure 2). Common polymor-582 Neuron 80, October 30, 2013 ª2013 Elsevier Inc.phisms in the CACNA1C gene, which encodes a pore-forming
subunit of the channel, are among the strongest associations
in both schizophrenia and bipolar disorder (Ferreira et al.,
2008; Psychiatric GWAS Consortium Bipolar Disorder Working
Group, 2011; Ripke et al., 2013). Common polymorphisms in
the CACNB2 gene, encoding a regulatory subunit of the same
channel, are also among the strongest associations for schizo-
phrenia and cross-disorder risk (Lee et al., 2013; Ripke et al.,
2013). Genes encoding the full set of potential subunits show a
statistically remarkable level of association as a group (Psychiat-
ric GWAS Consortium Bipolar Disorder Working Group, 2011).
Together, these results suggest that these channels exhibit a
surprising level of functional polymorphism in human popula-
tions and that this polymorphism shapes individuals’ risk for
schizophrenia and bipolar disorder.
Postsynaptic Components of Excitatory Synapses
Several genetic results implicate genes encoding the postsyn-
aptic components of excitatory synapses. The de novo CNVs
observed in schizophrenia patients have a strong statistical
tendency to affect the genes defined through proteomics as
components of the postsynaptic density (Kirov et al., 2012)
(Figure 2). In emerging exome sequencing data, these same
genes also appear to harbor loss-of-function variants in schizo-
phrenia cases more frequently than in controls and to be
enriched for de novo point mutations. Such results are likely to
strengthen as the ‘‘synaptome’’ is more completely delineated
in future experiments. As sample sizes expand, such results
will also begin to implicate genes individually rather than as
members of a group.
A Large Role for Regulatory DNA
While the genetic variation implicated in common-variant studies
maps to neurobiologically meaningful and related sets of genes,
it often maps to what are today the least interpretable compo-
nents of those genes. Most frequently, the implicated haplo-
types—sets of nearby alleles that segregate together—do not
overlap with protein-coding sequence but rather reside within
large introns and in sequences just upstream of the implicated
genes. These results suggest that much of the variation among
individuals in a population may arise not from broken proteins
but from variation in the quantitative levels or cell-type-specific
patterns with which these genes are expressed.
In organisms from plants to mammals, experiments on natural
variation in traits within species have often suggested a large role
for variation outside of the protein-coding sequences of genes.
Variation in the regulatory parts of genomes allows nature to
experiment with the place, time, quantity, and contingencies
with which gene products become available to cells—variation
that can shape behavioral variation among members of the
same species (Young et al., 1999; Insel and Shapiro, 1992). Non-
coding, regulatory parts of the genomemay be vehicles for inno-
vation on the rapid timescales that shape variation within species
in their natural environments. This may be a way in which natural
polymorphism is different from the mutations that scientists
introduce in the genomes of isogenic model organisms to ascer-
tain their ability to produce strong phenotypes that are outside
the range of natural, common variation in phenotypes for mem-
bers of that species.
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which rare, protein-disrupting variants cause severe, multiorgan
system damage, which in the brain is manifest as significant
intellectual disability and often epilepsy. In contrast, common,
regulatory variants in the same genes cause milder phenotypes
reflecting subsets of the tissues or cell types in which a gene is
expressed. For example, voltage-gated calcium channels are
essential for the function of the heart and other organs. Rare
gain-of-function mutations in the coding sequence of the chan-
nel subunit CACNA1C cause Timothy Syndrome, a multiorgan
disorder whose manifestations include potentially lethal cardiac
arrhythmias, immune deficiency, cognitive disability, and autism
(Splawski et al., 2004). Common variation in regulatory regions
of the CACNA1C gene appears to result in localized perturba-
tions of the gene’s activity; this variation associates with a quan-
titative increase in risk of schizophrenia and bipolar disorder
(approximately a 15% increase) without apparent association
to cardiac or immune phenotypes (Ripke et al., 2013). As
another example, disruptive mutations in the TCF4 coding
sequence cause Pitt-Hopkins syndrome, a condition character-
ized by microcephaly, severe intellectual disability (including, for
example, the almost complete absence of language), and
altered development of physical structures in many organ sys-
tems (Amiel et al., 2007). Specific noncoding variants in introns
of TCF4 associate with increased risk of schizophrenia (Lee
et al., 2012) without producing phenotypes in other organ sys-
tems. Regulatory sequence may allow tissue- and cell-type-
specific perturbations of a gene’s activity—modest, quantitative
perturbations rather than complete functional knockouts—and
likely represent a larger part of natural variation in phenotypes
that are observed in the general population. It is likely that com-
mon-variant association studies are giving us our first apprecia-
tion of how such regulatory, noncoding variation contributes to
natural variation in genetically complex disease phenotypes in
humans.
Further evidence for the regulatory nature of the variants impli-
cated in common-variant association studies comes from the
study of expression QTLs (eQTLs) in human tissues. The com-
mon variants that are implicated in genome-wide association
studies tend also to associate with quantitative measurements
of the expression levels of the same genes, especially when
gene expression ismeasured in the tissue relevant to the disease
(Nicolae et al., 2010; Richards et al., 2012).
Epigenetic Expression of Genetic Variation
Progress in the genome-scale analysis of chromatin states now
reveals hundreds of thousands of sites across the genome that
contain dynamic chromatin marks suggestive of tissue-specific
enhancer activity—the ability to regulate the expression of
nearby genes in specific tissues (Heintzman et al., 2009; Ernst
et al., 2011; Bernstein et al., 2012). Enhancer sites tend to exhibit
DNase hypersensitivity, suggesting that they are in open, acces-
sible chromatin; they are also flanked by characteristic histone
marks, including monomethylation of H3K4 and acetylation of
H3K27 (Heintzman et al., 2009; Ernst et al., 2011; Thurman
et al., 2012). Extensive new data from the ENCODE and Epige-
nomics Roadmap projects now document many ways in which
chromatin states and DNAmethylation implement the regulatoryinstructions that are encoded in genomic sequence, although
with a plasticity that makes them also responsive to cell type,
cell state, and environment.
Recent studies indicate that associations of disease to
common variants in the noncoding regions of genes involve
sequence variation in putative enhancers as defined by epige-
nomic profiling. These relationships follow a tissue-and-disease
logic: the common variants that associate to disease pheno-
types tend to reside in the tissue-specific enhancers defined
experimentally in the tissues thought to be most relevant to
each disease (Maurano et al., 2012). Such results reinforce the
conclusion that variation in gene regulation at many genomic
loci contributes to complex, polygenic disease by acting in a
tissue-specific manner.
The epigenomic profiles available in public resources today
are derived from homogenized brain tissues that are mixtures
of many cell types, including multiple neuronal and glial cell
populations. The utilization of genomic sequence elements is
ultimately a property of specific cell types, defined by their
developmental lineage and functional properties. It will be
important to understand how regulatory DNA elements are uti-
lized by each specific cell population, both under baseline and
stimulated conditions. An important breakthrough in helping
make such studies possible involves the development of tech-
niques, described below, for creating specific populations of
human neurons by cellular reprogramming—for example,
permitting the production of relatively pure populations of
cortical interneurons (Maroof et al., 2013). Such technologies
will make it possible to ascertain the specific segments of non-
coding DNA that are utilized by each cell population and to
connect specific disease-associated variants to perturbations
of specific types of neurons and glia.
From Genetic Findings to Biological Insights
The recent success of genetic studies for highly polygenic brain
disorders such as schizophrenia creates both a historical scien-
tific opportunity and a formidable challenge for neurobiology.
The opportunity inherent in having an initial molecular ‘‘parts
list’’ for these disorders is clear. However, the challenges are
also substantial. Historically, neurobiologists have investigated
gene function by making highly penetrant mutations in individual
genes, studying their effects on isogenic backgrounds, often
inbred laboratory mouse strains, and focusing on phenotypes
that are outside the range of natural phenotypic variation. In
this way, a great deal has been learned about some aspects
of rare and often severe monogenic diseases, whether of the
nervous system or of other organ systems (Shahbazian et al.,
2002; Pec¸a et al., 2011). However, as described above, the
genetic architecture of common polygenic diseases is quite
different from either the severe mutations of rare monogenic
disorders or artificial mutations (such as knockouts) made in lab-
oratory mice. The genetic architecture of common polygenic
diseases involves natural polymorphisms, including regulatory
variants, whose ultimate contribution to phenotype is just one
piece of a larger puzzle; such variants segregate on genetic
backgrounds that containmany other risk and protective factors.
The resulting challenges have led some to suggest that
biology should focus on the component of genetic architectureNeuron 80, October 30, 2013 ª2013 Elsevier Inc. 583
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Perspectivethat derives from rare, protein-altering mutations that are
assumed to have large effects (McClellan and King, 2010). We
think that to do so would miss the far larger scientific opportunity
emerging from studies of polygenic disorders. Indeed to do so
might miss the most important opportunities to address com-
mon serious diseases.
We recognize, however, that successful neurobiological anal-
ysis of polygenic disorders will require relatively new technolo-
gies and experimental approaches at scales that have not
been typical for neuroscience. For example, the interrogation
of large numbers of disease-associated genes and an even
larger number of allelic variants within them, both individually
and likely in combination, will require new approaches to living
model systems. It would neither be practical nor likely given
the modest penetrance of relevant alleles to make thousands
of transgenic mice.
Alleles Lead to Genes and Pathways
Before addressing possible approaches to investigating genetic
variants of modest penetrance that predispose to common dis-
eases including psychiatric diseases, it is worth arguing that the
scientific goals of such research are often misunderstood. It has
seemed to some that gene discovery would be valuable, above
all, to support new objective approaches to diagnosis, some-
thing that is sorely needed for psychiatric disorders (Hyman,
2007). There are at least two central obstacles in the way of
this goal. The first is that given the large number of common
and, more significantly, rare variants that likely contribute to
polygenic disorders such as schizophrenia and autism, a very
large catalog of risk alleles would be needed before a genetic
test could be used diagnostically with reasonable probability.
More important is the problem of pleiotropy, the phenomenon
in which one gene can influence multiple phenotypes. For vari-
ants ranging from large CNVs to common variants detected by
genome-wide association studies (GWASs), there is substantial
sharing of genetic risk-conferring alleles across psychiatric dis-
orders including autism, schizophrenia, bipolar disorder, major
depressive disorder, and attention-deficit hyperactivity disorder
(Sullivan et al., 2012; Smoller et al., 2013). Insofar as genetic tests
will come to play a role in diagnosis, they will likely bemost useful
when combined with phenotypic information such as cognitive
testing or imaging.
The far greater benefit of identifying genes is as clues to the
biology of disease. While disease-associated alleles can be ob-
jects of study in their own right, they are often the most effective
tools we have to identify genes relevant to pathogenesis. Beyond
that, genes can serve as a tool for discovering pathways or mo-
lecular networks involved in the neurobiology of disease or can
serve as the basis for molecular target discovery. The high pop-
ulation frequency of a common allele gives geneticists a foothold
to rigorously quantify its contribution to a phenotype and to
discover the effect in an unbiased genome-wide search. How-
ever, the particular allele does not establish an upper bound on
the biological significance of the gene. Alleles of small effect
routinely point to genes and pathways of large effect. For
example, common-variant association studies of human lipid
traits identified regulatory variants in an intron of the HMGCR
gene; the common variants explain only a 3 mg/dl increase in584 Neuron 80, October 30, 2013 ª2013 Elsevier Inc.levels of low-density lipoprotein (LDL) in the blood, representing
less than 1% of the heritability of this phenotype (Keebler et al.,
2009). But pharmacological manipulations of the same path-
way reduce LDL levels by 30%–60% and have done much to
reduce deaths from cardiovascular disease. Thus, for example,
the identification of risk alleles in GWASs for schizophrenia and
bipolar disorder implicated several genes encoding subunits of
L-type calcium channels in disease processes (Figure 2). The
identification of risk alleles in genetic studies of schizophrenia
and autism implicated protein networks in the postsynaptic spe-
cializations of excitatory synapses in these disorders (Figure 2).
Having found a gene of interest, using rare or common alleles
as pointers, neurobiologists are not limited to study the allele
by which the gene was found. They can proceed to manipulate
the gene and pathways in which its products function in powerful
and creative ways.
Living Systems to Investigate Gene Function
The most obvious limitation for use of mouse models to study
polygenic disorders, even with remarkably efficient new tools
for genome engineering (Wang et al., 2013), is that they are not
a high-throughput system. As such, the use of invertebrate ani-
mal models such as Drosophila or vertebrate models that repro-
duce more rapidly than mice, such as zebrafish, are likely to
prove important—even though high enough throughput will
remain a challenge. A second limitation to animal models is
posed by evolution. In recent years, there has been increasing
awareness, across many disease areas, that drugs that appear
efficacious in mouse models often lack efficacy in humans. In
nervous system disorders, substantial disillusionment with the
ability of animal models to predict treatment efficacy (Nestler
and Hyman, 2010; van der Worp et al., 2010) has contributed
to many pharmaceutical companies de-emphasizing neurologic
and psychiatric disorders. A recent workshop at the Institute of
Medicine posed the question, why do many therapeutics show
promise in preclinical animal models but then fail to elicit pre-
dicted effects when tested in humans (Institute of Medicine,
2013)? A key reason appears to be lack of evolutionary conser-
vation of key molecular networks and circuits. For example,
rodents are lissencephalic and lack a well-developed lateral
prefrontal cortex, an evolutionarily new region of cortex that
supports cognitive control in humans. Moreover, the largest
number of disease associations found by GWASs in schizo-
phrenia, for example, are in regulatory regions, the least well-
conserved genomic elements between humans and rodents
(Church et al., 2009) and indeed across all of evolution. Animal
models will remain critical, especially because human brain
disorders do not appear to be cell autonomous and, indeed,
affect brain circuitry that involves a large number of different
cell types. We would argue, however, that keeping both
throughput and evolution in mind, it is critical to use the simplest
living system possible that does not predispose to the blind
alleys posed by phenocopies.
A technology that has recently gained attention for its potential
utility in studying the function of human genes and their disease
risk alleles is the use of human neurons derived from fibroblasts
directly or through a stage of induced pluripotent cells (iPSCs) or
from human embryonic stem cells (hESCs) (Son et al., 2011;
Neuron
PerspectiveZhang et al., 2013). Such human cell-based systems have the
advantage of human transcriptional networks, indeed human
genomes. They also have the advantage of permitting high-
throughput interrogation of gene function when combined with
recent gene engineering technologies (Cong et al., 2013) that
are still being improved upon. It is also possible to study the func-
tion of one or several genes or gene variants against diverse
isogenic background from individuals with no known brain disor-
der as well as ‘‘rescue’’ patient-derived cells by engineering risk
variant out of their cells.
For all this promise, there is a long distance to travel before
cell-based systems are optimized as complements to carefully
interpreted animal models. The ability to differentiate
fibroblasts, iPS cells, or hESC cells into diverse mature neurons
and glia remains at an early stage, although significant progress
is being made (Son et al., 2011; Rouaux and Arlotta, 2013; Mar-
oof et al., 2013). In addition, technologies needed to compare
cultured neurons made by different methods with postmortem
human neurons, such as single-cell RNA sequencing or sin-
gle-cell proteomics, are at different and often early stages of
development. For schizophrenia, both cortical pyramidal neu-
rons and certain parvalbumin-expressing interneurons have
been implicated in the disease process (Lewis and Sweet,
2009); however, for essentially all neuropsychiatric disorders,
including schizophrenia, the relevant cell types to be modeled
remain poorly understood (see below). Another challenge,
based on the importance of synaptic proteins, described above,
in autism and schizophrenia, will be the ability to make repli-
cable and robust small neural circuits in vitro. Such hurdles
notwithstanding, the ability to make human neurons in vitro is
likely to prove a critically important approach to the study of
disease.
Finding the Cell Populations that Matter
Insights into the etiology of an illness often arise when science
identifies the specific cell populations in which a disease process
begins. Such insights would be of enormous value in schizo-
phrenia, bipolar disorder, and autism, in which the culpable
cell populations and circuits are not yet known. Genetics may
be particularly valuable in distinguishing phenomena that are
causal from phenomena that are mere markers for disease
progression or biological accommodations to the disease state:
since the genetic alleles existed long before the pathology
itself, their association to phenotypes must reflect a directional
effect on disease processes rather than a response to them.
We believe that an important direction in leveraging emerging
genetic results in polygenic disease is to use them to find the
cell types that matter to each disorder. We propose three ways
in which this will be possible. First, some of the implicated genes
may have patterns of expression that localize their effects to
specific cell populations. Second, regulatory variants may act
in geographically restricted ways, altering the expression level
in some but not all of the cell populations in which a gene is
expressed. Third, some populations of cells may show selective
vulnerability to a genetic perturbation, manifesting a difference in
cell state. Creative applications of RNA sequencing, for example,
analyzing individual cells, have the potential to help uncover
such relationships.High-Throughput Biology and Multidimensional Data
Analysis
Another potential strategy is to embrace the highly polygenic
nature of risk for many common disorders and to develop biolog-
ical research strategies that explore the functions of many genes
at once, looking for patterns and convergent phenotypes across
a large set of biological perturbations. Gene knockdown and
overexpression can be pursued in parallel in large numbers of
genes in parallel assays. Genome editing, which is being greatly
simplified by recent technological innovation (Cong et al., 2013;
Fenno et al., 2011; Zhang et al., 2013), may also soon be
amenable to high-throughput strategies. The challenge of mak-
ing sense of the long gene lists emerging from human genetics
may be one that is well served by a period of high-throughput
biology and multidimensional data analysis, which can be used
to develop testable hypotheses about the pathophysiology
involved in disease.
Conclusion
The combination of advances in genetic technologies and the
creation of large consortia to identify study populations adequate
to investigate polygenic diseasehas led to the first breakthroughs
in common, severe psychiatric disorders. As described, schizo-
phrenia is the best studied, with the expectation that more than
100 genome-wide significant associated loci will be known in
the near future. Bipolar disorder and autism await the identifica-
tion of larger populations, but the ‘‘playbook’’ for identifying
molecular risk factors in polygenic brain disorders is now clear.
As we have described, the exploitation of emerging findings to
achieve deep understandings of pathogenesis and to design
much needed new treatments is likely to depend on new ap-
proaches to neurobiology that are higher throughput than most
traditional investigations and the careful development and
exploitation of new model living systems, including human neu-
rons in vitro. We are just at the beginning of this journey, which
should provide rich new discoveries for basic science, but the
pressure to succeed is driven far more by the lack of effective
treatments for so many individuals with psychiatric disorders.
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